These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33038021)

  • 1. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis.
    Yokoyama Y; Aikawa T; Takagi H; Briasoulis A; Kuno T
    J Med Virol; 2021 Apr; 93(4):2084-2089. PubMed ID: 33038021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT; Zhang H; Chen T; Malhotra N
    Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19.
    Pan M; Vasbinder A; Anderson E; Catalan T; Shadid HR; Berlin H; Padalia K; O'Hayer P; Meloche C; Azam TU; Khaleel I; Michaud E; Blakely P; Bitar A; Huang Y; Zhao L; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Reiser J; Eugen-Olsen J; Hayek SS;
    J Am Heart Assoc; 2021 Dec; 10(24):e023535. PubMed ID: 34889102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
    Yin J; Wang C; Song X; Li X; Miao M
    Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
    Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies.
    Bavishi C; Whelton PK; Mancia G; Corrao G; Messerli FH
    J Hypertens; 2021 Apr; 39(4):784-794. PubMed ID: 33560054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
    J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
    Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
    PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
    Baral R; White M; Vassiliou VS
    Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renin-angiotensin system inhibitors on survival in kidney transplant recipients: A systematic review and meta-analysis.
    Jiang YM; Song TR; Qiu Y; Liu JP; Wang XD; Huang ZL; Lin T
    Kaohsiung J Med Sci; 2018 Jan; 34(1):1-13. PubMed ID: 29310811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry.
    López-Otero D; López-Pais J; Cacho-Antonio CE; Antúnez-Muiños PJ; González-Ferrero T; Pérez-Poza M; Otero-García Ó; Díaz-Fernández B; Bastos-Fernández M; Bouzas-Cruz N; Sanmartín-Pena XC; Varela-Román A; Portela-Romero M; Valdés-Cuadrado L; Pose-Reino A; González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):175-182. PubMed ID: 32600991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
    Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
    Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
    Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
    Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
    J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.